Buscar
Mostrando ítems 1-8 de 8
Do physicians correctly calculate thromboembolic risk scores?: a comparison of concordance between manual and computer‐based calculation of CHADS2 and CHA2DS2‐VASc scores
(Wiley, 2016-03-01)
[Abstract] BACKGROUND: Clinical risk scores, CHADS2 and CHA2 DS2 -VASc scores, are the established tools for assessing stroke risk in patients with atrial fibrillation (AF).
AIM: The aim of this study is to assess concordance ...
Usefulness of the 2MACE score to predicts adverse cardiovascular events in patients with atrial fibrillation
(Elsevier, 2017-09-19)
[Abstract] We investigated the incidence of nonembolic adverse events in 2 cohorts of patients with atrial fibrillation (AF) and validated the 2MACE score ([metabolic syndrome, age ≥75] [doubled]; [myocardial infarction ...
La INR durante los ictus y las hemorragias en pacientes con fibrilación auricular tratados con antagonistas de la vitamina K
(Elsevier, 2020-07)
[Resumen] Introducción y objetivos. La fibrilación auricular tiene un mal pronóstico asociado fundamentalmente al desarrollo de ictus. A pesar del uso de anticoagulantes, algunos pacientes pueden sufrir ictus y también ...
Relationship of Adverse Events to Quality of Anticoagulation Control in Atrial Fibrillation Patients With Diabetes: Real-World Data From the FANTASIIA Registry
(Taylor & Francis Group, 2020-06-17)
[Abstract] Background: Atrial fibrillation (AF) patients with diabetes (DM) have high risk of cardiovascular events. Purpose: To compare clinical characteristics, adverse outcomes and quality of anticoagulation in AF ...
Association of body mass index with clinical outcomes in patients with atrial fibrillation: a report from the FANTASIIA Registry
(NLM, 2019-12-24)
[Abstract]
Background.
Obesity and atrial fibrillation (AF) frequently coexist and independently increase mortality. We sought to assess the association between obesity and adverse events in patients receiving oral ...
Quality of anticoagulation with vitamin K antagonists
(Wiley, 2015-05-11)
[Abstract] Background. Vitamin K antagonists (VKA) have a narrow therapeutic range, and literature analysis reveals poor quality of anticoagulation control. We sought to assess the prevalence of poor anticoagulant control ...
Choice of new oral anticoagulant agents versus vitamin K antagonists in atrial fibrillation: FANTASIIA study
(SAGE, 2015-07-30)
[Abstract] Introduction: Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patients with AF receive chronic anticoagulation, either with vitamin K antagonists (VKAs) or with non-VKA ...